RINVOQ VS Xeljanz

A JAK inhibitor called RINVOQ acts within your cells to stop certain impulses that are considered to be responsible for inflammation. RINVOQ, a once-daily medication, has been demonstrated in clinical tests to help manage symptoms in 6 illnesses.

Adults with moderate to severe rheumatoid arthritis (RA) who have tried one or more tumour necrosis factor (TNF) blockers but found that they did not relieve their symptoms or were intolerable. Adults with active psoriatic arthritis (PsA) who have tried one or more TNF blockers but found that they did not relieve their symptoms or were intolerable.

On the other hand, since its original approval in 2012, XELJANZ has been prescribed for individuals with moderate to severe rheumatoid arthritis for more than 9 years. Adults with moderate to severe ulcerative colitis received approval to use XELJANZ in 2017, while adults with active ankylosing spondylitis received approval in 2018.

A Janus kinase (JAK) inhibitor called XELJANZ works to block JAK pathways from within cells, which are thought to be involved in inflammation. Watch to find out more about the XELJANZ science and how JAK inhibitors are supposed to function.